Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Glioblastoma With Oligodendroglial Component Clear all

Completed Phase 3 Interventional

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

NCT01480479

View directory record Official record

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Interventions: Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 74 more

Source: ClinicalTrials.gov public record

Updated Jan 15, 2018 · Synced May 21, 2026, 7:40 PM EDT

Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328

View directory record Official record

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions: Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2020 · Synced May 21, 2026, 7:40 PM EDT

Completed Phase 1 Interventional

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

NCT00960492

View directory record Official record

Conditions: Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
Interventions: XL184, temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older

Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 5 more

Source: ClinicalTrials.gov public record

Updated Sep 21, 2014 · Synced May 21, 2026, 7:40 PM EDT

Completed Phase 2 Interventional Results available

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

NCT03746080

View directory record Official record

Conditions: Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
Interventions: Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT), Radiation Therapy; Drug · Radiation
Lead sponsor: Lawrence D Recht; Other
Eligibility: 18 Years to 75 Years

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Source: ClinicalTrials.gov public record

Updated Nov 13, 2025 · Synced May 21, 2026, 7:40 PM EDT